Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

aHUS caused by complement dysregulation: new therapies on the horizon.

Waters AM, Licht C.

Pediatr Nephrol. 2011 Jan;26(1):41-57. doi: 10.1007/s00467-010-1556-4. Epub 2010 Jun 18. Review. Erratum in: Pediatr Nephrol. 2013 Jan;28(1):165.

2.

Genetic Atypical Hemolytic-Uremic Syndrome.

Noris M, Bresin E, Mele C, Remuzzi G.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2007 Nov 16 [updated 2016 Jun 9].

3.

[Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].

Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C.

Rev Med Interne. 2011 Apr;32(4):232-40. doi: 10.1016/j.revmed.2009.09.039. Epub 2011 Mar 3. French.

4.

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G.

Clin J Am Soc Nephrol. 2010 Oct;5(10):1844-59. doi: 10.2215/CJN.02210310. Epub 2010 Jul 1.

5.

Transplantation in atypical hemolytic uremic syndrome.

Kavanagh D, Richards A, Goodship T, Jalanko H.

Semin Thromb Hemost. 2010 Sep;36(6):653-9. doi: 10.1055/s-0030-1262887. Epub 2010 Sep 23. Review.

PMID:
20865642
6.

Atypical hemolytic uremic syndrome.

Loirat C, Frémeaux-Bacchi V.

Orphanet J Rare Dis. 2011 Sep 8;6:60. doi: 10.1186/1750-1172-6-60. Review.

7.

[Atypical HUS caused by complement-related abnormalities].

Yoshida Y, Matsumoto M.

Rinsho Ketsueki. 2015 Feb;56(2):185-93. doi: 10.11406/rinketsu.56.185. Review. Japanese.

PMID:
25765799
8.

Atypical hemolytic uremic syndrome: update on the complement system and what is new.

Hirt-Minkowski P, Dickenmann M, Schifferli JA.

Nephron Clin Pract. 2010;114(4):c219-35. doi: 10.1159/000276545. Epub 2010 Jan 14. Review.

9.

Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M; European Working Party on Complement Genetics in Renal Diseases.

J Am Soc Nephrol. 2013 Feb;24(3):475-86. doi: 10.1681/ASN.2012090884. Epub 2013 Feb 21.

10.

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.

Transplant Proc. 2012 Dec;44(10):3037-40. doi: 10.1016/j.transproceed.2012.07.141.

PMID:
23195022
11.

Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

Wong EK, Goodship TH, Kavanagh D.

Mol Immunol. 2013 Dec 15;56(3):199-212. doi: 10.1016/j.molimm.2013.05.224. Epub 2013 Jun 28. Review.

12.

Alternative complement pathway assessment in patients with atypical HUS.

Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V.

J Immunol Methods. 2011 Feb 28;365(1-2):8-26. doi: 10.1016/j.jim.2010.12.020. Epub 2011 Jan 6. Review.

PMID:
21215749
13.

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis.

Szarvas N, Szilágyi Á, Tasic V, Nushi-Stavileci V, Sofijanova A, Gucev Z, Szabó M, Szabó A, Szeifert L, Reusz G, Rusai K, Arbeiter K, Müller T, Prohászka Z.

Ital J Pediatr. 2014 Dec 11;40:101. doi: 10.1186/s13052-014-0101-7.

14.
15.

Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.

Tran H, Chaudhuri A, Concepcion W, Grimm PC.

Pediatr Nephrol. 2014 Mar;29(3):477-80. doi: 10.1007/s00467-013-2630-5. Epub 2013 Nov 13.

PMID:
24221349
16.

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.

Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R.

Ther Apher Dial. 2018 Apr;22(2):178-188. doi: 10.1111/1744-9987.12641. Epub 2017 Dec 17.

PMID:
29250893
18.

Atypical hemolytic uremic syndrome.

Kavanagh D, Goodship TH, Richards A.

Semin Nephrol. 2013 Nov;33(6):508-30. doi: 10.1016/j.semnephrol.2013.08.003. Review.

19.

Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Noris M, Remuzzi G.

Curr Opin Nephrol Hypertens. 2013 Nov;22(6):704-12. doi: 10.1097/MNH.0b013e328365b3fe. Review.

PMID:
24076560
20.

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E.

Clin J Am Soc Nephrol. 2009 Aug;4(8):1312-6. doi: 10.2215/CJN.01090209. Epub 2009 Jun 25.

Supplemental Content

Support Center